Hematology Frontier

Lentiviral vectors are commonly used in engineering CAR-T cells; however, they can sometimes lead to false positive results for Human Immunodeficiency Virus (HIV) following CAR-T infusion. Identifying such false positives can be challenging.

Multiple myeloma is a clonal plasma cell proliferative disorder that has seen significant therapeutic advancements over the past few decades due to deepening biological research. With the development of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, Chimeric Antigen Receptor T-cell (CAR-T) therapy, and other new drugs, the survival and prognosis for patients with multiple myeloma have undergone milestone changes. From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting was held in Glasgow, UK. At the conference, Professor Reuben Benjamin from King's College Hospital in London gave a special report on the clinical application and future prospects of hematopoietic stem cell transplantation and CAR-T cell therapy in multiple myeloma patients. Hematology News invited Professor Benjamin to share his insights with a broad audience.

The 2024 China Clinical Oncology Society (CSCO) Guidelines Conference was held in Jinan on April 26-27, 2024. As always, the conference updated and released multiple CSCO cancer treatment guidelines. Professor Tiejun Gong, Deputy Director of the Harbin Institute of Hematologic Oncology, gave an insightful interpretation of the leukemia section in the "2024 CSCO Guidelines on Malignant Hematology." After the conference, "Oncology Frontier - Hematology Frontier" invited Professor Gong to introduce the characteristics and updates in leukemia treatment in the 2024 CSCO Malignant Hematology Guidelines, discuss current challenges in leukemia treatment, and express his views on potential improvements.

From April 14 to 17, 2024, the 50th Annual Congress of the European Society for Blood and Marrow Transplantation (EBMT) was held with great ceremony in Glasgow, UK. The conference focused on the latest advancements in stem cell transplantation and cell therapy, advancing patients with hematological diseases towards better clinical prognoses. At this congress, Dr. Li Gao from Soochow University Affiliated Children's Hospital reported on a study.

Induction therapies with high remission rates, combined with high-dose chemotherapy and autologous stem cell transplantation (ASCT), have significantly improved the prognosis for multiple myeloma (MM) patients. Despite this, patients still inevitably experience disease progression or relapse. One of the key goals in this research field is how to maintain remission in patients after induction therapy and ASCT. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting took place in Glasgow, UK, from April 14 to 17, 2024. The conference focused on the latest advancements in stem cell transplantation and cellular therapy, driving better clinical outcomes for patients with hematological diseases and cancers. At this conference, Professor Jean-Luc Harousseau, Chairman of the French National Health Authority and Director of the René Gauducheau Cancer Center at the University of Nantes, delivered an insightful presentation on optimizing induction therapy strategies for multiple myeloma patients before ASCT. "Hematology Frontier" invited Professor Harousseau to share his insights on continuously optimizing pre-ASCT induction therapy for multiple myeloma patients.

The 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting was held in Glasgow, UK, from April 14th to 17th, 2024. The conference focused on the latest developments in stem cell transplantation and cell therapy, pushing forward better clinical outcomes for patients with hematologic diseases and blood cancers. At this meeting, Dr. Gao's team presented six research findings, covering innovative explorations and practices in hematopoietic stem cell transplantation, as well as the combined application of CAR-T and hematopoietic stem cell transplantation. They shared advanced concepts and research findings, contributing China's wisdom to the global stage and sharing innovative results with the world. This article includes a translation and compilation of two posters from Professor Tong Wu’s team for the enjoyment of our readers.

As spring blossoms and nature revives, the 15th Experimental Diagnostic Hematology Conference and the 1st Conference on Rare Blood Diseases, hosted by the Chinese Medical Association, were grandly held in the city of Gusu on March 23-24, 2024. The conference invited renowned experts and scholars from the field of hematology both domestically and internationally to deliver enlightening academic presentations and engage in thematic discussions. The aim was to foster academic exchange and cooperation in the fields of experimental diagnostic hematology and rare blood diseases, to share the latest research findings, discuss industry trends, and collectively promote the prosperity of hematology in China. At the conference, Professor Yujie Wu from Jiangsu Provincial People's Hospital (The First Affiliated Hospital of Nanjing Medical University) delivered an excellent presentation titled "Standardized Flow Cytometry Detection of CLL-MRD," which is specially compiled here for our readers' enjoyment.